Entrada Therapeutics (TRDA) Gains from Investment Securities (2022 - 2025)
Historic Gains from Investment Securities for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$36000.0.
- Entrada Therapeutics' Gains from Investment Securities fell 350000.0% to -$36000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.5 million, marking a year-over-year increase of 42020.55%. This contributed to the annual value of $4.6 million for FY2024, which is 9404.26% down from last year.
- As of Q3 2025, Entrada Therapeutics' Gains from Investment Securities stood at -$36000.0, which was down 350000.0% from -$40000.0 recorded in Q2 2025.
- Entrada Therapeutics' Gains from Investment Securities' 5-year high stood at $69.0 million during Q2 2023, with a 5-year trough of -$33.0 million in Q2 2022.
- In the last 4 years, Entrada Therapeutics' Gains from Investment Securities had a median value of -$1000.0 in 2024 and averaged $6.6 million.
- As far as peak fluctuations go, Entrada Therapeutics' Gains from Investment Securities skyrocketed by 30901.84% in 2023, and later crashed by 350000.0% in 2025.
- Entrada Therapeutics' Gains from Investment Securities (Quarter) stood at $4.3 million in 2022, then skyrocketed by 1520.09% to $69.0 million in 2023, then tumbled by 90.33% to $6.7 million in 2024, then tumbled by 100.54% to -$36000.0 in 2025.
- Its last three reported values are -$36000.0 in Q3 2025, -$40000.0 for Q2 2025, and -$45000.0 during Q1 2025.